首页> 美国卫生研究院文献>Indian Journal of Clinical Biochemistry >Effect of fluoxetine on weight reduction in obese patients
【2h】

Effect of fluoxetine on weight reduction in obese patients

机译:氟西汀对肥胖患者减轻体重的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Obesity is one of the most important health problems, which many people suffer from it. As a chronic disease, it is a precipitating factor for many medical conditions like hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, sleep apnea syndrome and some malignancies (breast, uterus, prostate and colon carcinoma). With attention to this fact that obesity is an independent risk factor associated with significant increase in morbidity and mortality, treatment of overweight individuals is very important. One of the medications for short-term weight loss is fluoxetin. In this clinical trial study, fluoxetin effect on weight loss induction during 8 weeks was investigated. 201 cases with BMI between 25–42 were selected randomly (113 female and 88 male) and all received fluoxetine (40 mg daily) for 8 weeks. Measurement was carried out after the 4th and 8th week of administration and 4 weeks after end of treatment. Management of 9 cases (4 due to weight gain and 5 due to headache) were discontinued after 4 weeks of treatment. Data assessments were performed using t-test and SPSS program. Mean body weight at first visit was 89.32±13.30kg. At the 4th, 8th week of treatment and 4 weeks after study, the mean body weight of cases reached 86.09±13.27 (p=0.00), 82.69±11.31 (p=0.00) and 81.97±13.26 (p=0.00) respectively. Mean BMI at first visit was 34.90±5.20kg/m2. At 4th, 8th weeks of treatment it was 33.72±5.20kg/m2 and 32.40±5.18kg/m2 respectively. Mean weight loss at 4th and 8th weeks of treatment was 3.24kg and 6.67kg respectively without any weight gain at the end of the 4th week after discontinuation of the drug. Fluoxetine is an effective, well-tolerated and relatively safe drug for short-term treatment of obesity.
机译:肥胖是最重要的健康问题之一,许多人都因此而遭受痛苦。作为一种慢性疾病,它是许多医学疾病的诱发因素,例如高血压,糖尿病,高脂血症,冠状动脉疾病,睡眠呼吸暂停综合症和某些恶性肿瘤(乳腺癌,子宫癌,前列腺癌和结肠癌)。注意到肥胖是与发病率和死亡率显着增加相关的独立危险因素这一事实,对超重个体的治疗非常重要。短期减肥的药物之一是氟西汀。在这项临床试验研究中,研究了氟西汀在8周内对减肥的诱导作用。随机选择201例BMI在25-42之间的患者(女性113例,男性88例),均接受氟西汀(每日40 mg)治疗8周。在给药的第4周和第8周后以及治疗结束后4周进行测量。治疗4周后中止治疗9例(因体重增加4例,因头痛5例)。使用t检验和SPSS程序进行数据评估。初诊时的平均体重为89.32±13.30kg。在治疗的第4周,第8周和研究后第4周,患者的平均体重达到86.09±13.27(p = 0.00),82.69±11.31( p = 0.00)和81.97±13.26(p = 0.00)。初诊时的平均BMI为34.90±5.20kg / m 2 。在治疗的第4周,第8周时,分别为33.72±5.20kg / m 2 和32.40±5.18kg / m 2 。治疗第4周和第8周的平均体重减轻分别为3.24kg和6.67kg,在第4周结束时没有任何体重增加>停药后一周。氟西汀是短期治疗肥胖症的有效,耐受性良好和相对安全的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号